Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.
about
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial VirusRSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction.A single amino acid mutation (I1012F) of the RNA polymerase of marine viral hemorrhagic septicemia virus changes in vitro virulence to rainbow trout gill epithelial cellsRefining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genesAttenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization.Inhibitors of the interferon response enhance virus replication in vitro.Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trialsEnhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.Live-attenuated respiratory syncytial virus vaccines.Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β.Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignRespiratory syncytial virus: current progress in vaccine development.Central nervous system alterations caused by infection with the human respiratory syncytial virus.Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeuticsNovel therapies and vaccines against the human respiratory syncytial virus.Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.Ongoing developments in RSV prophylaxis: a clinician's analysis.Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.Human Respiratory Syncytial Virus: An Introduction.Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
P2860
Q26748856-1FBCAB80-76A1-424F-B0D1-394EEE2F2B93Q30577192-03EA5E6C-0514-43AB-B592-301454B2BCCAQ33744051-1409B163-F9D4-46F6-B2CC-C75316E09810Q34237741-59C51325-125A-44FB-AC15-9540D0B9BED2Q34583420-3C359C6F-61D1-4807-8FB6-D9F8F2E5B2EEQ35414495-4110BABF-BBA9-4A66-B67F-673D039995A7Q35761061-91D6BD0A-7EFD-4B95-9CA3-179A55EC1D09Q35973617-642EA502-C0F2-4189-84E4-AF6732E96CEEQ36086315-71D67CB8-F011-432E-8141-6975560A4411Q36692801-668B576B-9F06-411B-B05B-DB28BE44184AQ36725539-B46A3497-3E96-4DEF-B22C-6E813670967BQ37347267-930BF226-60FE-4077-A1F7-38A31B558D00Q37713874-6EFC0D3A-DDE3-44BE-A9FE-2D40ADB916A6Q37729137-B744B960-6377-439B-9436-35F3380728CDQ38079432-512396E2-C03C-4900-B810-3D6ECCB926E2Q38260281-1A3E5357-88DD-4888-B6EB-7E6156B4639FQ38363535-ACBA4355-6B01-4BBE-93CA-A760DA3E9938Q38604787-D0709143-12E7-468B-BAB9-7793C1BBBD2FQ38803541-58C709C5-07E4-4669-9B0B-41BA29046E7EQ39303791-60692A5F-0C92-4F4F-BD45-CEBAC0C57D08Q40072947-65CE9CB7-24CB-4D99-96AB-22F7DF0BF5D6Q40187606-C81AF8D1-FB5A-456E-9F28-2F6B769EE35CQ40312271-D9D18621-3D8F-44D5-8EC4-41A7B9B9E6BDQ40597806-CC0C143E-63A5-4C19-87C6-F5D0E222FCC3Q47555408-38B441C9-25BA-4F07-BCF5-4E77EFB2C8BFQ54095931-EB5CEB44-709D-418B-A485-9463B237EE9F
P2860
Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Respiratory syncytial virus mo ...... at physiological temperature.
@ast
Respiratory syncytial virus mo ...... at physiological temperature.
@en
type
label
Respiratory syncytial virus mo ...... at physiological temperature.
@ast
Respiratory syncytial virus mo ...... at physiological temperature.
@en
prefLabel
Respiratory syncytial virus mo ...... at physiological temperature.
@ast
Respiratory syncytial virus mo ...... at physiological temperature.
@en
P2093
P2860
P356
P1433
P1476
Respiratory syncytial virus mo ...... at physiological temperature.
@en
P2093
Christine C Winter
Cindy Luongo
Peter L Collins
Ursula J Buchholz
P2860
P304
P356
10.1128/JVI.02769-12
P407
P577
2012-12-12T00:00:00Z